Thomsen Pharma ApS: Financial statements 2025
CVR: 40620060
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
Thomsen Pharma ApS (CVR 40620060) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -14,978 and a net result of DKK -16,315 compared with DKK -4,005,382 the year before. Equity in the 2025 report amounted to DKK 607,713. The solvency ratio was 93.9%.
- Gross Profit
- DKK -14,978
- Profit/Loss
- DKK -16,315
- Equity
- DKK 607,713
- Total Assets
- DKK 646,875
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | -15K | -16K | 608K | 0 |
| 2024 | - | -15K | -4M | 624K | - |
| 2023 | - | -6K | -6K | 4.6M | - |
| 2022 | - | -27K | -540K | 4.6M | - |
| 2021 | - | -19K | 484K | 5.2M | - |
Official annual report
How creditworthy is Thomsen Pharma ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
Thomsen Pharma ApS has published its annual report for 2024. Gross profit came to DKK -15,092, and the net result was DKK -4,005,382.
About Thomsen Pharma ApS
Thomsen Pharma ApS is a Danish company of the type Anpartsselskab based in Glamsbjerg, founded in 2019. The company is registered under the industry Ikke-finansielle holdingselskaber. The management consists of Mikael Søndergaard Thomsen. The company is owned by Mikael Søndergaard Thomsen. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -14,978 and a net result of DKK -16,315 compared with DKK -4,005,382 the year before. Equity in the 2025 report amounted to DKK 607,713.